Osmotica Pharmaceuticals (NASDAQ:OSMT) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research downgraded shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) from a hold rating to a sell rating in a research report report published on Tuesday morning, Zacks.com reports.

According to Zacks, “Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women’s health. The company’s product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey. “

Other equities analysts have also issued reports about the company. Wells Fargo & Co restated a buy rating on shares of Osmotica Pharmaceuticals in a report on Friday, August 9th. Jefferies Financial Group set a $10.00 target price on Osmotica Pharmaceuticals and gave the company a buy rating in a report on Monday, August 12th. Barclays assumed coverage on Osmotica Pharmaceuticals in a report on Tuesday, June 11th. They set an overweight rating and a $11.00 target price on the stock. Finally, ValuEngine upgraded Osmotica Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $13.00.

NASDAQ OSMT opened at $2.80 on Tuesday. Osmotica Pharmaceuticals has a fifty-two week low of $2.20 and a fifty-two week high of $9.90. The stock’s 50-day moving average is $3.35 and its two-hundred day moving average is $4.33. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.49 and a current ratio of 1.78.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last posted its earnings results on Thursday, August 8th. The company reported $0.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.06. Osmotica Pharmaceuticals had a negative return on equity of 32.14% and a negative net margin of 97.91%. The company had revenue of $57.53 million for the quarter, compared to analyst estimates of $57.90 million. On average, equities research analysts expect that Osmotica Pharmaceuticals will post -0.25 EPS for the current fiscal year.

Several large investors have recently modified their holdings of the company. Northern Trust Corp grew its position in shares of Osmotica Pharmaceuticals by 5.6% in the second quarter. Northern Trust Corp now owns 99,449 shares of the company’s stock valued at $378,000 after purchasing an additional 5,230 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Osmotica Pharmaceuticals in the first quarter valued at about $45,000. Deutsche Bank AG acquired a new stake in shares of Osmotica Pharmaceuticals in the fourth quarter valued at about $111,000. Citadel Advisors LLC acquired a new stake in shares of Osmotica Pharmaceuticals in the second quarter valued at about $120,000. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in shares of Osmotica Pharmaceuticals in the second quarter valued at about $142,000. 12.36% of the stock is currently owned by institutional investors.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Further Reading: Call Option Volume

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.